Novo Nordisk Lawsuit 2026: Securities Fraud Case Survives, No Settlement Yet
Quick Answer
- Is it legit? Yes. A federal judge allowed part of the securities fraud case to proceed on July 28, 2026.
- How much? Not yet determined. No settlement has been reached. No payout figures exist.
- Key deadline? The lead plaintiff deadline was September 30, 2025. It has passed. No new deadlines set.
If you bought Novo Nordisk stock and lost money when the company’s CagriSema trial results came in below expectations, you may be watching this case closely. Here’s the honest update: the lawsuit is real, part of it survived a motion to dismiss, but there is no money on the table yet. No settlement. No fund. No claim form.
The case centers on the REDEFINE-1 trial, a Phase 3 study of CagriSema, Novo’s next-generation weight loss drug. When the company announced on December 20, 2024 that CagriSema helped patients lose 20.4% of their body weight, below its own 25% target, the stock crashed. American Depositary Receipts fell 17.8% that day . Investors lost billions. Some of them sued, alleging they were misled about how the trial was designed.
On July 28, 2026, U.S. District Judge Robert Kirsch in Trenton, New Jersey ruled that investors can pursue claims that Novo and a top executive misled them about CagriSema’s tolerability by falsely implying the dosing protocols were the same as in previous trials . The judge dismissed other claims, including those about “fixed doses” and the 25% weight loss projection .
This article breaks down exactly what survived, what got dismissed, who may be covered, and what happens next in 2026.
The Facts
| Case | In re Novo Nordisk A/S Securities Litigation, No. CV 25-713 (RK) (JBD) |
|---|---|
| Court | U.S. District Court for the District of New Jersey |
| Status | Motion to dismiss granted in part, denied in part. Case proceeding. No settlement. |
| Fund Size | Not yet confirmed. No settlement fund exists. |
| Est. Per Person | Not yet determined. No payout structure exists. |
| Claim Deadline | Not applicable. No claims process has been opened. |
| Administrator | Not yet appointed. JND Legal Administration referenced in prior notices . |
| Proof Needed | Not applicable. No claim form exists. |
Is the Novo Nordisk Lawsuit Still Active in 2026?
Yes, the Novo Nordisk securities lawsuit is still active. Judge Kirsch’s July 28, 2026 ruling kept one major theory alive: that Novo’s Executive Vice President of Development, Martin Holst Lange, misled investors about CagriSema’s tolerability .
The case is not settled. It is in the discovery phase. Both sides will exchange documents, emails, and internal communications. Depositions will follow. This is the expensive, slow part of litigation. A class has not been certified yet. No trial date has been set.
What investors need to understand is that “surviving a motion to dismiss” is not the same as winning. It means the claims are plausible enough to proceed. Novo has denied the allegations and called them “meritless” . The company intends to defend itself vigorously.
Key Takeaway: The Novo Nordisk securities case survived a major hurdle in July 2026, but it is still in early stages. No settlement has been announced, and no payout timeline exists.
How Much Could You Get from the Novo Nordisk Lawsuit?
You cannot get any money from the Novo Nordisk lawsuit right now. There is no settlement fund, no court-approved payout structure, and no claims process. Any website or service promising a payout from this case is not telling you the truth.
If the case eventually settles or goes to trial and plaintiffs win, damages would be calculated based on stock losses tied to the alleged fraud. But that is a hypothetical. No number exists today.
The class period for the main securities case runs from November 2, 2022 through December 19, 2024 . Investors who purchased Novo Nordisk ADRs during that window and held them through the December 20, 2024 price drop may be potential class members if a class is certified.
A separate, related case has a shorter class period: May 7, 2025 through July 28, 2025 . That case involves different allegations. Its lead plaintiff deadline was September 30, 2025.
Reality Check: No one texts you settlement money first. Filing a claim in any class action is always free. Third-party “claim helpers” charging fees to file Novo Nordisk settlement claims are unnecessary and likely predatory. There is no Novo Nordisk settlement to claim.
What Did Novo Nordisk Actually Do to Trigger the Lawsuit?
Investors allege Novo Nordisk misled them about the design of the REDEFINE-1 trial for CagriSema. The company combined semaglutide, the active ingredient in Wegovy, with cagrilintide, an amylin analog . Analysts expected strong results. Novo projected at least 25% average weight loss .
Here is what the company allegedly did not disclose: the Phase 3 trial used a “flexible protocol” that let patients modify their own dosing throughout the 52-week maintenance period . In earlier trials, dose modification was allowed only if a patient would otherwise quit the drug entirely. The Phase 3 protocol gave trial investigators a more active role in managing tolerability, including re-escalation attempts and dietary guidance .
The result was that only 57% of patients received the highest dose of CagriSema . The drug helped patients lose 20.4% of their body weight, below the 25% target and below Eli Lilly’s Zepbound benchmark of 22.5% . The stock dropped 17.8% on December 20, 2024 .
Judge Kirsch found that investors sufficiently pleaded that Lange intended to defraud them by falsely implying the dosing protocols were the same as previous trials . The judge said Lange’s repeated statements that dose escalation would “not introduce more tolerability issues” put the subject “in play” and created a duty to disclose the flexible protocol .
What Claims Survived the Motion to Dismiss?
Only one category of claims survived Judge Kirsch’s July 28, 2026 ruling: statements about CagriSema’s tolerability .
The judge dismissed claims about:
- General descriptions of the Phase 3 trial’s structure and dosing, because statements about “comparing” and “investigating” a 2.4 mg dose were literally true
- A “fixed dose combination” or “FDC” reference in a slide footnote, because the term referred to the fixed ratio of the two drugs, not an inflexible dosage regimen
- Lange’s projection of at least 25% weight loss, which the judge called “aspirational” and not a basis for fraud
The surviving claims focus on specific statements Lange made in response to analyst questions. He said dose escalation would “not introduce more tolerability issues,” that Novo could achieve greater efficacy “without having to compromise on safety and tolerability,” and that CagriSema’s tolerability profile would be “broadly in line” with existing GLP-1 treatments .
The judge ruled that by making those affirmative characterizations, Lange assumed a duty to disclose the flexible dosing protocol. The company’s own post-class-period statements acknowledged incorporating a “flexible protocol,” which undermined Novo’s argument that nothing had changed .
Who May Qualify for the Novo Nordisk Securities Class?
You may qualify for the Novo Nordisk securities class if you purchased or acquired Novo Nordisk American Depositary Receipts during the class period and suffered losses tied to the December 2024 stock drop.
The main class period is November 2, 2022 through December 19, 2024 . The lead plaintiffs are three pension and retirement funds that purchased Novo Nordisk ADRs during that window .
Eligibility checklist:
- You purchased Novo Nordisk ADRs between November 2, 2022 and December 19, 2024
- You held those securities through the December 20, 2024 price decline
- You suffered financial losses tied to the CagriSema trial disclosure
- You did not serve as a lead plaintiff in another overlapping case
The separate, shorter class period case runs May 7, 2025 through July 28, 2025 . That case involves different allegations and a different lead plaintiff deadline that has already passed.
No claim form exists yet. If a class is certified and a settlement is reached, a notice program would inform eligible class members. Until then, there is nothing to file.
How Do You Check If You’re Included in the Novo Nordisk Class?
You cannot check your inclusion in the Novo Nordisk class right now because no class has been certified and no settlement administrator has been appointed for a claims process.
If a settlement is reached in the future, the court would order a notice program. Class members would receive notice by mail or email using records from brokerage firms and transfer agents. A claims administrator would be appointed. A claims website would open. A deadline would be set.
The settlement administrator referenced in prior Novo Nordisk litigation notices is JND Legal Administration . But that reference is from an earlier, unrelated case. Do not send personal information to any entity claiming to process Novo Nordisk CagriSema settlement claims today.
Contact information if a future settlement is announced: Novo Nordisk Securities Litigation, c/o JND Legal Administration, P.O. Box 91154, Seattle, WA 98111 .
What Other Lawsuits Is Novo Nordisk Facing in 2026?
Novo Nordisk is fighting multiple legal battles beyond the securities case. These are separate matters with different plaintiffs, courts, and outcomes.
Insulin pen products liability: Griffin Health Services sued Novo Nordisk in Connecticut federal court over insulin pens used on multiple patients without adequate warnings. The court denied Novo’s summary judgment motions in July 2026, allowing failure to warn, design defect, and negligence claims to proceed . The pens lacked a “single patient use only” warning until the FDA required it in February 2015 .
Compounded GLP-1 litigation: Novo Nordisk sued Hims & Hers in February 2026 over patent infringement related to compounded Wegovy. The parties settled in March 2026. Hims agreed to sell branded Wegovy and Ozempic on its platform and stop advertising compounded GLP-1 drugs . Novo also reached a settlement with LifeRxMD in September 2026 that restricts the pharmacy’s marketing of compounded drugs .
Misleading advertising against Eli Lilly: Novo Nordisk sued Eli Lilly in July 2026, alleging Lilly’s direct-to-consumer ads comparing Zepbound and Mounjaro to Wegovy and Ozempic rely on outdated data and omit critical context . Lilly denies the claims and says its advertising is truthful and grounded in the SURMOUNT-5 head-to-head trial .
What Happens Next in the Novo Nordisk Securities Case?
Expected Q4 2026: Discovery continues. Both sides exchange documents and take depositions. This phase can take 12 to 18 months.
Expected 2027: Class certification motion. Plaintiffs will ask the court to certify a class of investors. Novo will oppose. The outcome determines who is bound by the case.
Expected 2027 or 2028: Summary judgment or trial. If the case survives summary judgment, it could go to trial. Most securities class actions settle before trial.
No deadline for you: There is nothing to file and no date to calendar for a payout. Watch for a class notice if a settlement is reached.
Frequently Asked Questions
Is there a Novo Nordisk settlement?
No. There is no settlement in the Novo Nordisk securities fraud case. The case is proceeding in discovery after a July 28, 2026 ruling allowed part of it to continue.
How much will Novo Nordisk investors get?
Nothing has been determined. No settlement fund exists. No payout structure has been announced. Amounts, if any, would depend on future settlement or trial outcomes.
Can I still join the Novo Nordisk lawsuit?
The lead plaintiff deadline for the main case was September 30, 2025. It has passed. You cannot become a lead plaintiff. If a class is certified later, you may automatically be included if you meet the class definition.
What is the Novo Nordisk class period?
The main securities class period is November 2, 2022 through December 19, 2024. A separate case has a class period of May 7, 2025 through July 28, 2025.
What did Novo Nordisk allegedly do wrong?
Investors allege Novo and an executive misled them about the CagriSema trial’s dosing protocol. The company allegedly implied the trial used the same dosing rules as prior trials when it actually used a flexible protocol that let patients adjust doses.
Do I need a lawyer to join the Novo Nordisk class?
No. Class members in securities class actions do not need their own lawyers. The lead plaintiffs and class counsel represent the class. You only need a lawyer if you want to opt out and pursue your own case.
What happened to Novo Nordisk stock?
Novo Nordisk ADRs fell 17.8% on December 20, 2024, after the company reported CagriSema’s weight loss results came in below its 25% target .
Is Novo Nordisk facing other lawsuits?
Yes. Novo faces products liability claims over insulin pens in Connecticut, patent litigation over compounded GLP-1 drugs, and a misleading advertising lawsuit against Eli Lilly.
